Management of Cardiovascular Disease in Kidney Disease (MaCK) Study
Status:
Recruiting
Trial end date:
2023-09-30
Target enrollment:
Participant gender:
Summary
Cardiovascular disease (CVD) is the largest concerns for patients with Chronic kidney disease
(CKD). At present time the investigators do not have proven effective strategies to reduce
high CVD related deaths in CKD. This study assesses a novel therapy (hydroxychloroquine, HCQ)
for the treatment of CVD in patients with CKD. This is the first human proof-of-concept study
and is planned to be conducted among US Veterans, who suffer from both CKD and CVD at a
disproportionately greater rates. The outcome of this study has the potential to provide an
entirely new line of therapy for the treatment of CVD in CKD.